Literature DB >> 17980690

Polymorphisms in the endothelial nitric oxide synthase gene and bone density/ultrasound and geometry in humans.

K Cho1, S Demissie, J Dupuis, L A Cupples, S Kathiresan, T J Beck, D Karasik, D P Kiel.   

Abstract

Nitric oxide (NO), produced by endothelial cells, is a signaling molecule synthesized from l-arginine by nitric oxide synthases (NOS). NO is known to reduce the ratio of receptor activator of nuclear factor KappaB (RANKL)/osteoprotegerin (OPG), leading to decreased osteoclastogenesis and a reduction in bone resorption. Endothelial nitric oxide synthase (eNOS or NOS3) is the predominant constitutive isoform of nitric NOS within bone. Recently, a NOS3 polymorphism, Glu298Asp, previously implicated in osteoporosis, failed to demonstrate an association with bone mineral density (BMD), although there was some indication of an association with selected geometry indices. Since a single polymorphism does not capture all of the potential variants in a given gene, we investigated a broader coverage of the NOS3 gene with bone density/ultrasound and geometry indices in a sample of unrelated individuals from the Framingham Offspring Study. Our results indicated that the Glu298Asp polymorphism was not associated with BMD but suggested some haplotype-based associations in the linkage disequilibrium (LD) region that included the Glu298Asp polymorphism with several geometry indices. Although our findings exhibited several associations with selected bone density/ultrasound and geometry indices, the nominally significant associations are regarded as primarily hypothesis generating and suggest that replication in other samples is needed. Thus, NOS3 genetic variation does not appear to be a major contributor to adult bone density/ultrasound and geometry in our sample.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17980690      PMCID: PMC2386517          DOI: 10.1016/j.bone.2007.09.051

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  39 in total

1.  Genome screen for a combined bone phenotype using principal component analysis: the Framingham study.

Authors:  D Karasik; L A Cupples; M T Hannan; D P Kiel
Journal:  Bone       Date:  2004-03       Impact factor: 4.398

2.  Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data.

Authors:  T J Beck; C B Ruff; W W Scott; C C Plato; J D Tobin; C A Quan
Journal:  Calcif Tissue Int       Date:  1992-01       Impact factor: 4.333

Review 3.  Epidemiology of hip fractures: implications of the exponential increase with age.

Authors:  L J Melton
Journal:  Bone       Date:  1996-03       Impact factor: 4.398

4.  The Physical Activity Scale for the Elderly (PASE): development and evaluation.

Authors:  R A Washburn; K W Smith; A M Jette; C A Janney
Journal:  J Clin Epidemiol       Date:  1993-02       Impact factor: 6.437

5.  Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study.

Authors:  M T Hannan; K L Tucker; B Dawson-Hughes; L A Cupples; D T Felson; D P Kiel
Journal:  J Bone Miner Res       Date:  2000-12       Impact factor: 6.741

6.  Endothelial function and carotid intima-media thickness in young healthy subjects among endothelial nitric oxide synthase Glu298-->Asp and T-786-->C polymorphisms.

Authors:  Umberto Paradossi; Enrica Ciofini; Aldo Clerico; Nicoletta Botto; Andrea Biagini; Maria Giovanna Colombo
Journal:  Stroke       Date:  2004-04-08       Impact factor: 7.914

7.  Interactions of interleukin-6 promoter polymorphisms with dietary and lifestyle factors and their association with bone mass in men and women from the Framingham Osteoporosis Study.

Authors:  Serge L Ferrari; David Karasik; Jun Liu; Samev Karamohamed; Alan G Herbert; L Adrienne Cupples; Douglas P Kiel
Journal:  J Bone Miner Res       Date:  2004-01-05       Impact factor: 6.741

8.  Age, gender, and body mass effects on quantitative trait loci for bone mineral density: the Framingham Study.

Authors:  D Karasik; L A Cupples; M T Hannan; D P Kiel
Journal:  Bone       Date:  2003-09       Impact factor: 4.398

9.  Estrogen receptor beta polymorphisms are associated with bone mass in women and men: the Framingham Study.

Authors:  Amanda M Shearman; David Karasik; Kristen M Gruenthal; Serkalem Demissie; L Adrienne Cupples; David E Housman; Douglas P Kiel
Journal:  J Bone Miner Res       Date:  2003-12-22       Impact factor: 6.741

10.  An investigation of coronary heart disease in families. The Framingham offspring study.

Authors:  W B Kannel; M Feinleib; P M McNamara; R J Garrison; W P Castelli
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

View more
  5 in total

1.  Expression of endothelial nitric oxide synthase protein is not necessary for mechanical strain-induced nitric oxide production by cultured osteoblasts.

Authors:  V Das-Gupta; R A Williamson; A A Pitsillides
Journal:  Osteoporos Int       Date:  2012-03-09       Impact factor: 4.507

2.  Circadian fluctuations of endothelial nitric oxide synthase activity in females with rheumatoid arthritis: a pilot study.

Authors:  Kateryna Zaichko; Mykola Stanislavchuk; Nataliia Zaichko
Journal:  Rheumatol Int       Date:  2020-02-05       Impact factor: 2.631

Review 3.  Evidence for pleiotropic factors in genetics of the musculoskeletal system.

Authors:  David Karasik; Douglas P Kiel
Journal:  Bone       Date:  2010-02-10       Impact factor: 4.398

4.  A susceptibility haplotype within the endothelial nitric oxide synthase gene influences bone mineral density in hypertensive women.

Authors:  Monica Singh; Puneetpal Singh; Surinder Singh; Pawan Kumar Juneja; Taranpal Kaur
Journal:  J Bone Miner Metab       Date:  2013-11-10       Impact factor: 2.626

5.  Relationships between endothelial nitric oxide synthase gene polymorphisms and osteoporosis in postmenopausal women.

Authors:  Shun-zhi Liu; Hong Yan; Wei-kun Hou; Peng Xu; Juan Tian; Li-fang Tian; Bo-feng Zhu; Jie Ma; She-min Lu
Journal:  J Zhejiang Univ Sci B       Date:  2009-08       Impact factor: 3.066

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.